This trial (n=60) investigated the effect of MDMA (75mg) on the formation of memories. This was tested by simulating a crime (virtual reality). The trial found no significant effect of heightened vulnerability to external suggestions from MDMA.
Status: Completed
Start date: 2018-09-12
Phase I
Blinded
60 participants
Interventional
This neuroimaging trial (n=24) investigates the effects of one high dose of psilocybin (25mg) in those with depression. It specifically investigates the synaptic density (synapses are the connections between brain cells; neurons). The aim is to assess the relationship between the antidepressant and neurotrophic (growth within brain) effects of psilocybin.
Status: Not yet recruiting
Start date: 2023-01-01
Phase II
Open
24 participants
Interventional
This small open-label trial (n=8) will test the safety of two doses of the ayahuasca brew containing DMT (1.0mg to 1.4mg/kg). The trial is sponsored by Psychae and is done in collaboration with St. Vincent's Hospital in Melbourne Australia.
Status: Not yet recruiting
Start date: 2022-11-05
Phase I
Open
8 participants
Interventional
This open-label trial will assess the bioavailability of COMP360 (psilocybin) in healthy volunteers (n=14). The trial will assess the effects of both 5 and 25 mg doses of COMP360.
Status: Recruiting
Start date: 2022-06-16
Phase I
Open
14 participants
Interventional
This double-blind placebo-controlled trial aims to assess the effects of DMT on healthy participants who smoke (n=50).
Status: Recruiting
Start date: 2021-01-08
Phase I
Blinded
50 participants
Interventional
This pilot study aims to establish a dosing regimen for intravenous (IV) psilocybin that will allow the drug to be administered to asleep participants without awakening them and assess whether this dosing regimen produces a psychedelic experience.
Status: Not yet recruiting
Start date: 2023-03-01
Phase I
Open
15 participants
Interventional
This open-label trial (n=12), also known as PSILODEP-PILOT is the first to test psilocybin in patients in the UK. The study found psilocybin (10-25mg, x2) to be well-tolerated.
Status: Completed
Start date: 2015-04-01
Phase II
Open
12 participants
Interventional
This open-label trial (n=20) seeks to evaluate psilocybin-assisted interpersonal social and rhythm therapy (IPSRT) for treatment-resistant depression. Participants will receive two doses of psilocybin and eight sessions of psychotherapy.
Status: Not yet recruiting
Start date: 2022-11-15
Phase I
Open
20 participants
Interventional
This project tests the safety, tolerability, pharmacokinetics (PK, the amount of study drug in your blood) and pharmacodynamics (PD, how the study drug affects your body) of single doses of KUR-101 in 58 healthy participants.
Status: Recruiting
Start date: 2022-02-15
Phase I
Blinded
58 participants
Interventional
This is the second part of COMPASS Pathwhays’ Phase III clinical trial program exploring the effects of fixed repeated doses of COMP360 (25mg, 10mg & 1mg) in participants (n=568) with treatment-resistant depression (TRD).
Status: Planned
Start date: 2022-12-31
Phase III
Blinded
568 participants
Interventional
This is the first part of COMPASS Pathwhays' Phase III clinical trial program comparing the effects of a single dose of COMP360 (25mg) to placebo in participants (n=378) with treatment-resistant depression (TRD).
Status: Recruiting
Start date: 2022-11-31
Phase III
Blinded
378 participants
Interventional
This open-label trial (n=30) seeks to evaluate the acute and subacute effects of inhaled DMT. Participants will be given a low dose (7mg/70kg) and then two hours later a higher dose (49mg/70kg). Participants will not receive psychological support.
Status: Recruiting
Start date: 2022-06-01
Phase I
Open
30 participants
Interventional
This trial (n=48) will follow therapists as they embark on their own psychedelic experiences. The trial's focus is on the benefits and risks to both the therapists and the patients (and their interaction).
Status: Not yet recruiting
Start date: 2022-12-01
Not Applicable
Open
48 participants
Interventional
The purpose of this study is to evaluate the safety, tolerability, and potential efficacy of psilocybin-assisted psychotherapy to reduce post-traumatic stress disorder (PTSD) severity in a sample of individuals with PTSD.
Status: Enrolling by invitation
Start date: 2022-11-01
Phase I
Open
30 participants
Interventional
This study will test the feasibility, safety, and evidence for the efficacy of psilocybin administration in participants with obsessive-compulsive disorder (OCD).
Status: Not yet recruiting
Start date: 2022-09-30
Phase I
Open
30 participants
Interventional
The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans.
Status: Not yet recruiting
Start date: 2023-01-01
Phase II
Open
15 participants
Interventional
This is an open-label randomized study looking at an 8-week Mindfulness-Based Stress Reduction (MBSR) curriculum vs. an 8-week MBSR curriculum + a group psilocybin-assisted psychotherapy intervention for frontline healthcare providers struggling with symptoms of depression and burnout associated with the SARS-CoV-2 pandemic.
Status: Not yet recruiting
Start date: 2023-01-01
Open
24 participants
Interventional
This double-blind cross-over trial (n=24) investigates the effect of repeated doses of psilocybin (2x) at varying doses of psilocybin (1 or 10mg) on concussion headache.
Status: Recruiting
Start date: 2019-03-28
Phase I
Blinded
24 participants
Interventional
This double-blind trial (n=60) by Algernon Pharmaceuticals will give participants several 6-hour (you read that right) infusions of DMT. The first part will start with a 1.5mg bolus followed by 6.3mg (0.105mg p/m) each hour. If read correctly, the second part of the study will do six doses over six hours but doesn't specify if a continuous infusion will also be given.
Status: Not yet recruiting
Start date: 2022-11-01
Phase I
Blinded
60 participants
Interventional
This open-label trial (n=20) will take EEG measures on participants who receive two doses of psilocybin (up to 25mg). Next to the brain measures, participants will be studied up to six months later.
Status: Not yet recruiting
Start date: 2022-08-15
Phase I
Open
20 participants
Interventional
This open-label trial (n=24) investigates the difference between those who are and aren't taking antidepressants (SSRIs) who will receive SPL026 (DMT fumarate). As a Phase I study, the main concern is safety and tolerability. With 24 participants, some signal on effectiveness might be detected.
Status: Not yet recruiting
Start date: 2022-10-01
Open
24 participants
Interventional
This RCT (n=24) does a direct comparison, the first one in a double-blind trial, of MDMA, psilocybin, and 2C-B (a novel psychedelic with MDMA & psilocybin-like effects). Next to a placebo, the dosages of MDMA (125mg) and psilocybin (25mg) are high, whilst that of 2C-B will be a variety of doses (10, 20, 30mg). All participants will receive all compounds and a placebo (cross-over study design).
Status: Not yet recruiting
Start date: 2022-12-31
Phase I
Blinded
24 participants
Interventional
This observational trial (n=1000) investigates the personality differences between those who use drugs (including psychedelics) and those who don't. The study uses the Quantified Citizen app to gather the data.
Status: Not yet recruiting
Start date: 2022-11-01
Not Applicable
Open
1000 participants
Observational
This open-label trial (n=10) serves as a preliminary study to see if psilocybin (in combination with psychotherapy) may help treat anxiety, depression and chronic pain (demoralization) in cancer survivors.
Status: Not yet recruiting
Start date: 2022-08-31
Phase I
Open
10 participants
Interventional
This second trial of COMP360 (psilocybin) by COMPASS will investigate the effectiveness of the psychedelic for anorexia in 60 patients.
Status: Not yet recruiting
Start date: 2022-08-01
Phase II
Blinded
60 participants
Interventional
This double-blind placebo-controlled trial (n=36) investigates the effects of psilocybin on heart health (Cardiac Repolarization), the dosing includes one (not defined) extra high dose of psilocybin (supratherapeutic).
Status: Active, not recruiting
Start date: 2022-06-22
Phase II
Blinded
36 participants
Interventional
This double-blind, randomised study (n=65) will investigate if every third-day mini-dosing (25μg) of LSD for three weeks (7x dosing) alleviates chronic cluster headaches (CCH).
Status: Not yet recruiting
Start date: 2023-05-01
Phase II
Blinded
65 participants
Interventional
This double-blind study (n=128) will investigate if LSD (150-250μg, 2x) will be effective in treating alcoholism (AUD). This will be compared to an 'active' placebo of 10μg LSD. The study, when conducted, will be the largest modern study of LSD for AUD.
Status: Not yet recruiting
Start date: 2023-01-01
Phase II
Blinded
128 participants
Interventional
This open-label Phase I study (n=8) will compare the bioavailability of IV and oral psilocybin (5mg vs 25mg). It is expected to yield similar pharmacokinetic and psychedelic (subjective) effects, but more consistent blood levels for IV.
Status: Not yet recruiting
Start date: 2022-10-01
Phase I
Open
8 participants
Interventional
This open-label trial (n=30) will test whether the MDMA-assisted psychotherapy protocol is also effective in treating PTSD incurred by healthcare workers during the Covid pandemic.
Status: Not yet recruiting
Start date: 2022-10-01
Phase II
Open
30 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
